Stay updated with breaking news from Zara Lockshin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its...
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of kidney... | June 5, 2023
FinancialContent fully hosted finance channel
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapyMALVERN, Pa., May 18, 2023 -- Galera Therapeutics, Inc. , a clinical-stage... | June 11, 2023
Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives... | May 11, 2023